Kura Oncology FY2025 EPS Estimate Reduced by Leerink Partnrs

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Kura Oncology in a note issued to investors on Tuesday, November 4th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($2.07) per share for the year, down from their previous estimate of ($0.40). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2025 earnings at $0.19 EPS and FY2026 earnings at ($1.71) EPS.

Other analysts have also recently issued research reports about the company. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. JMP Securities reiterated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, October 20th. Guggenheim began coverage on shares of Kura Oncology in a report on Thursday, September 4th. They issued a “neutral” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Wednesday, October 8th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Kura Oncology Price Performance

Shares of KURA opened at $10.16 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 5.12. The company has a 50 day moving average price of $9.17 and a 200-day moving average price of $7.30. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $19.73. The stock has a market capitalization of $884.12 million, a PE ratio of -4.10 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%.

Insider Activity

In related news, COO Kathleen Ford sold 6,892 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $61,614.48. Following the transaction, the chief operating officer owned 63,375 shares in the company, valued at approximately $566,572.50. This represents a 9.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Troy Edward Wilson sold 36,615 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $327,338.10. Following the transaction, the chief executive officer directly owned 246,853 shares of the company’s stock, valued at $2,206,865.82. This represents a 12.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 78,058 shares of company stock valued at $697,839. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BVF Inc. IL lifted its holdings in shares of Kura Oncology by 202.0% in the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock valued at $51,177,000 after buying an additional 5,186,660 shares during the period. EcoR1 Capital LLC lifted its holdings in Kura Oncology by 59.1% in the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock valued at $24,234,000 after acquiring an additional 1,559,702 shares during the period. Armistice Capital LLC boosted its position in Kura Oncology by 13.3% in the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock worth $43,375,000 after purchasing an additional 772,000 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after purchasing an additional 738,761 shares during the period. Finally, AQR Capital Management LLC increased its holdings in shares of Kura Oncology by 407.8% during the 1st quarter. AQR Capital Management LLC now owns 760,332 shares of the company’s stock valued at $5,018,000 after purchasing an additional 610,604 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.